



ODJFS P&T Committee Meeting

Wednesday, January 11, 2012

Riffe Building Room 1960, 77 S. High St., Columbus, OH 43215

10:00 AM

- 1) Conflict of Interest Policy
P&T Committee members to sign agreement
- 2) Interested party presentations *
- 3) Old Business
- 4) New Business: Drugs under consideration
 - a) Preferred Drug List New Drugs
 - i) Analgesics – Long-Acting Opioids: Nucynta ER CII (tapentadol extended-release) tablets, Janssen
 - ii) Injectable Anti-Rheumatic Drugs: Orencia (abatcept) for subcutaneous administration, Bristol-Myers Squibb
 - b) Other New Drugs
 - i) Horizant (gabapentin enacarbil) extended-release tablets, GlaxoSmithKline
 - ii) Gralise (gabapentin) once-daily tablets, Depomed
 - iii) Xarelto (rivaroxaban) tablets, 15mg and 20mg, Janssen

* Any interested party may request to present information to the P&T Committee.
Guidelines are posted at

<http://jfs.ohio.gov/ohp/bhpp/omdp/pdf/GuidelinesforSubmissions.pdf>

**Ohio Department of Job and Family Services
Office of Ohio Health Plans**

**Pharmacy and Therapeutics Committee
Conflict of Interest Policy**

Purpose: To require members of the ODJFS Pharmacy and Therapeutics Committee to abide by this policy so that scientific and economic data serves as the primary basis in rendering objective decisions about drugs being considered for coverage by Ohio Health Plans.

Definition: A potential “conflict of interest” may exist when a committee member has a relationship with a manufacturer of the medication or class of medications being considered that could inappropriately influence his/her judgment, or the judgment of other members. This may include a relationship with a manufacturer of a drug which competes with the drug under consideration. A relationship with a manufacturer may include any of the following:

- Acceptance of honoraria
- Participation in speaker’s bureau
- Acceptance of support for travel for professional or education activities
- Acceptance of research support
- Relationship valued at \$500 or more with one company
- Consultant arrangement

Policy Statements

1. A member shall not participate in the discussion of an issue that is before the committee unless he/she has first disclosed any potentially relevant conflict of interest.
2. The committee will determine if a specific activity or relationship represents a potential conflict of interest and whether the member disclosing a potentially relevant conflict should continue to participate in the discussion.

Procedure: Committee members must sign this agreement once each year.

Signature _____ Date _____

Printed Name _____